Journal article
Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial
M Jun, K Harris, HJL Heerspink, SV Badve, MJ Jardine, S Harrap, P Hamet, M Marre, N Poulter, S Kotwal, M Gallagher, V Perkovic, J Chalmers, M Woodward
Diabetes Obesity and Metabolism | Published : 2021
DOI: 10.1111/dom.14351
Abstract
There are limited data on whether estimated glomerular filtration rate (eGFR) variability modifies the risk of future clinical outcomes in type 2 diabetes (T2D). We assessed the association between 20-month eGFR variability and the risk of major clinical outcomes in T2D among 8241 participants in the ADVANCE trial. Variability in eGFR (coefficient of variation [CVeGFR]) was calculated from three serum creatinine measurements over 20 months. Participants were classified into three groups by thirds of CVeGFR: low (≤6.4; reference), moderate (>6.4 to ≤12.1) and high (>12.1). The primary outcome was the composite of major macrovascular events, new or worsening nephropathy and all-cause mortality..
View full abstractGrants
Funding Acknowledgements
The ADVANCE trial was funded by grants from the National Health and Medical Research Council (NHMRC) of Australia and from Servier. MJ is supported by a Scientia Fellowship from the University of New South Wales (Sydney, Australia). MW is supported by a National Health and Medical Research Council of Australia Investigator Grant and Program Grant.